Clinical Guidelines & Position Statements
|
Publication Date
|
UPDATED: Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Guideline for the Management of Axial Spondyloarthritis
- Click here to view the latest version of the Guideline on MAGICApp
- Published versions of the guideline in Journal of Rheumatology:
|
April 2026 |
UPDATED: CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs.
- Click here to view the latest version of the guideline on MAGICapp
- Published versions of the guideline in Journal of Rheumatology:
- Click here to view patient decision aid: Your Rheumatoid Arthritis (RA) is Well Controlled with a Biologic or Targeted Medicine: Should you Take Less Medicine?
|
April 2026 |
| Updated: Canadian Rheumatology Association Position Statement on Criteria for Access to Targeted Agents for Rheumatoid Arthritis in Canada PDF |
March 2026 |
| NEW: Canadian Rheumatology Association Position Statement for Vaccinations in Patients with Rheumatic Diseases PDF |
February 2026 |
| Canadian Rheumatology Association Position Statement on Hydroxychloroquine Monitoring Guidance for Optical Coherence Tomography PDF |
December 2025 |
| Canadian Rheumatology Association Position Statement for Access to JAK Inhibitors for Children in Canada PDF |
November 2025 |
| CRA Position Statement on Quebec’s Bill 2 : Protecting Rheumatology Care and Physician Well-being PDF |
November 2025 |
CRA/CanRIO guidelines for the management of baseline immunosuppression in individuals with pre-existing rheumatic diseases initiating immune checkpoint inhibitors.
- Click here to view Part 1 in the Journal of Rheumatology (Part 1 includes recommendations for pre-existing inflammatory arthritides -rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis)
- Click here to view Part 2 in the Journal of Rheumatology (Part 2 includes recommendations for pre-existing systemic autoimmune rheumatic diseases -systemic sclerosis, systemic lupus erythematosus, Sjögren’s disease, myositis, vasculitis, Behcet’s disease, sarcoidosis)
- Click here to read the CRA/CanRIO guideline for the management of baseline immunosuppression in individuals with pre-existing rheumatic diseases initiating immune checkpoint inhibitors on MagicApp
|
September 2025 |
| Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems
|
June 2025 |
| UPDATED: Canadian Rheumatology Association Guidelines Handbook PDF |
June 2025 |
| UPDATED: CRA Position Statement on Safety of Hydroxychloroquine in the Treatment of Rheumatic Diseases PDF |
March 2025 |
| Canadian Rheumatology Association Position Statement on PDE5 inhibitors for the treatment of severe Raynaud’s Phenomenon PDF |
July 2024 |
| Canadian Rheumatology Association Position Statement on Biologic Access PDF |
June 2024 |
| Canadian Rheumatology Association Position Statement on National Pharmacare PDF |
June 2024 |
| Position Statements on Priority Areas to Support the Sustainability of the Canadian Rheumatology Workforce PDF |
December 2022 |
The CRA living guidelines for the Screening, Monitoring and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
- Click here to view on MAGICapp
- Click here to view published manuscript in the Journal of Rheumatology
- Click here to view the infographics designed for providers.
- Click here to view the infographic designed for patient families
|
October 2022 |
| Bridging the Gaps: Optimizing the Transition from Pediatric to Adult Rheumatology Care PDF |
July 2022 |
| CRA Recommendation on Three Doses of mRNA Vaccine for Preventing COVID-19 PDF |
November 2021 |
Updated CRA Recommendation on COVID-19 Vaccination in Persons with Autoimmune Rheumatic Disease PDF
– Decision Tool available here |
November 2021 |
CRA Consensus Statement on the Best Practices for Virtual Care in Rheumatology
– Transitioning Care – New ‘Living’ Resource for CRA Members |
September 2021 |
| CRA Position Statement on Virtual Care PDF |
April 2021 |
CRA Position Statement on COVID-19 and Hydroxychloroquine Supply PDF
– Frequently Asked Questions |
April 2020 |
| Canadian Rheumatology Association Policy on Potential Conflicts of Interest in the Guideline Development Process PDF |
June 2019 |
Canadian Rheumatology Association Position Statement on Medical Cannabis Use in Rheumatic Disease
– Frequently Asked Questions |
January 2019 |
| Canadian Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus |
August 2018 |
| Canadian Position Statement on Opioid Therapy PDF |
November 2017 |
| Canadian Position Statement on Management of Juvenile Idiopathic Arthritis |
October 2016 |
| Canadian Review on Cannabinoid Treatments for Rheumatic Diseases |
November 2015 |
| Canadian Recommendations for the Management of Spondyloarthropathy |
April 2014 |
Cardiovascular Risk with Diclofenac: Response to Health Canada PDF
Reviewed by Therapeutics Committee in November 2021 and no changes made. |
November 2014 |
| Chronic pain, Diclofenac and Cardiovascular Risk: Management Algorithm PDF |
June 2014 |
| Canadian Confidence with Cannabinoids in Rheumatic Diseases: A Survey of Rheumatologists PDF |
November 2014 |
| Canadian Recommendations for Management of RA |
August 2012 |
